Business
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced that compelling preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225), has been accepted for presentation at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held on October 23 – 25, 2025 in Carlsbad, CA. The presentation
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression levels","length":205,"tagName":"p","attribs":{}},{"type":"text","content":"- Extended follow-up in prostate cancer models demonstrated durable anti-tumor responses with ATNM-400, exceeding those achieved with the androgen receptor pathway inhibitor (ARPI), enzalutamide","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced that compelling preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225), has been accepted for presentation at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held on October 23 – 25, 2025 in Carlsbad, CA. The presentation will highlight ATNM-400's ability to induce robust, durable anti-tumor activity in metastatic castration-resistant prostate cancer (mCRPC) models, including tumors resistant to standard-of-care therapies such as the androgen receptor pathway inhibitor (ARPI), enzalutamide (Xtandi®, Astellas/Pfizer) and the PSMA-targeted therapy, 177Lu-PSMA-617 (active agent in Pluvicto®, Novartis) as well as superior efficacy compared to 225Ac-PSMA-617.","length":989,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":97,"url":"https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yUttGl4ecQ0sM9T7v.HK4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","width":400,"height":97}},"href":"https://mma.prnewswire.com/media/730678/Actinium_Pharmaceuticals_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"ATNM-400 PCF Presentation Information","length":37,"tagName":"p"},{"type":"text","content":"Title: ATNM-400, a...